RARE
Ultragenyx Pharmaceutical Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Ultragenyx Pharmaceutical Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Ultragenyx Pharmaceutical has 20 disclosed suppliers and 5 disclosed customers in SEC filings.
Ultragenyx Pharmaceutical Inc.
16.06
SentenceFor the year ended December 31, 2025, 45% of our total revenues were generated by our collaboration partner KKC.
basisRARE FY2025 revenue $673M
RARE 10-Kaccession 0001193125-26-057329
SentenceThe supply price to us for commercial sales of Crysvita in Latin America is 30% of net sales, which is higher than the typical cost of sales for companies focused on rare diseases.
basisRARE FY2025 revenue $673M
RARE 10-Kaccession 0001193125-26-057329
SentenceThe Company has a license agreement with REGENXBIO, Inc., or REGENX, for an exclusive, sublicensable, worldwide commercial license under certain intellectual property for preclinical and clinical research and development, and commercialization of drug therapies using REGENX's licensed patents for the treatment of OTC deficiency and GSD1a.
SentenceIn May 2022, the Company announced an exclusive License Agreement for the AAV gene therapy for UX111 with Abeona for the treatment of MPS IIIA.
RARE 10-Kaccession 0000950170-25-023312
SentenceIn March 2023, the Dojolvi drug product manufacturer Aenova Haupt Pharma Wolfratshausen GmbH notified us of their intent to close the facility by the end of 2023.
RARE 10-Kaccession 0000950170-25-023312
SentenceUnder the terms of this license agreement, as amended, BRI exclusively licensed to the Company its territories for certain intellectual property related to Dojolvi for the treatment of LC-FAOD.
RARE 10-Kaccession 0000950170-25-023312
SentenceIn October 2024, we filed a suit against Catalent Maryland, Inc. and Catalent Pharma Solutions, LLC (collectively, Catalent) in the Superior Court of the State of Delaware alleging that Catalent fraudulently mispresented its manufacturing capabilities and serially breached the terms of its manufacturing agreement with us.
RARE 10-Kaccession 0001193125-26-057329
SentenceIn October 2024, we filed a suit against Catalent Maryland, Inc. and Catalent Pharma Solutions, LLC (collectively, Catalent) in the Superior Court of the State of Delaware alleging that Catalent fraudulently mispresented its manufacturing capabilities and serially breached the terms of its manufacturing agreement with us.
RARE 10-Kaccession 0001193125-26-057329
SentenceIn October 2024, we filed a suit against Catalent Maryland, Inc. and Catalent Pharma Solutions, LLC (collectively, Catalent) in the Superior Court of the State of Delaware alleging that Catalent fraudulently mispresented its manufacturing capabilities and serially breached the terms of its manufacturing agreement with us.
RARE 10-Kaccession 0001193125-26-057329
SentenceThe pharmaceutical-grade drug substance for Dojolvi is manufactured by IOI Oleo GmbH, or IOI Oleo, in Germany under an exclusive worldwide supply agreement.
RARE 10-Kaccession 0000950170-25-023312
SentenceUnder the collaboration agreement, KKC manufactures and supplies Crysvita for sales in Latin American territories and we pay KKC a transfer price of 30% of net sales.
RARE 10-Kaccession 0000950170-25-023312
SentenceUnder the collaboration agreement, KKC manufactures and supplies Crysvita, which is purchased by the Company for sales in Latin America and Turkey, and charges the Company a transfer price of 30 % of net sales.
RARE 10-Kaccession 0000950170-25-023312
SentenceThe Mepsevii drug substance is manufactured by Rentschler Biopharma SE, or Rentschler, under non-exclusive commercial supply and services agreements.
RARE 10-Kaccession 0000950170-25-023312
SentenceUnder the terms of this license agreement, SLU granted the Company an exclusive worldwide license to make, have made, use, import, offer for sale, and sell therapeutics related to SLU's beta-glucuronidase product for use in the treatment of human diseases.
RARE 10-Kaccession 0000950170-25-023312
SentenceIn October 2020, the Company entered into a strategic Collaboration and License Agreement with Solid Biosciences Inc., or Solid, and received an exclusive license for any pharmaceutical product that expresses Solid's proprietary microdystrophin construct from AAV8 and variants thereof in clade E for use in the treatment of Duchenne muscular dystrophy and other diseases resulting from lack of functional dystrophin, including Becker muscular dystrophy.
RARE 10-Kaccession 0000950170-25-023312
SentenceIn addition, we have in-licensed various patents and patent applications owned by the University of Pennsylvania relating to our DTX301, and UX701 product candidates.
RARE 10-Kaccession 0001193125-26-057329
SentenceFor the year ended December 31, 2024, 49% of our total revenues were generated by our collaboration partner KKC.
RARE 10-Kaccession 0000950170-25-023312
SentenceIn December 2024, we entered into a manufacturing and supply agreement with Mereo where we are responsible for the supply of setrusumab to Mereo in the Mereo territory.
RARE 10-Kaccession 0000950170-25-023312
SentencePursuant to the agreement, OMERS paid $500.0 million to us in consideration for the right to receive 30% of the future royalty payments due to us from KKC based on net sales of Crysvita in the U.S. and Canada under the terms of the KKC Collaboration Agreement.
RARE 10-Kaccession 0000950170-25-023312
SentencePursuant to the agreement, RPI paid us $320.0 million in consideration for our right to receive royalty payments on the net sales of Crysvita in the European Union, or the EU, the UK, and Switzerland, effective January 1, 2020, under the terms of our Collaboration and License Agreement with Kyowa Kirin Co., Ltd., or KKC.
RARE 10-Kaccession 0000950170-25-023312
Expected move
Inputsspot 16.10exp Nov 6ATM strike 16ATM straddle 1.67IV 94%